Pancreatic Cancer- Pipeline Insight, 2025

DelveInsight's, "Pancreatic Cancer- Pipeline Insight, 2025,"report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Pancreatic Cancer Understanding

Pancreatic Cancer: Overview

Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. It exhibits aberrant autocrine and paracrine signaling cascades that promote pancreatic cancer cell proliferation, migration, invasion, and metastasis.

Pancreatic cancer also exhibits metabolic abnormalities and insensitivity to growth-inhibitory pathways. Loss of negative growth constraints is best exemplified by aberrant TGFB signaling, which occurs due to increased expression of TGFB isoforms. Although TGFB is a physiological tumor suppressor, it promotes tumor progression in pancreatic cancer and many other solid tumors by exerting paracrine effects within the tumor microenvironment that lead to enhanced growth and metastasis. TGFB can also directly induce pancreatic cancer cell proliferation by activating non-canonical signaling through mitogen-activated protein kinase (MAPK) phosphorylation, proto-oncogene tyrosine-protein kinase Src (SRC), and AKT phosphorylation, and by upregulating WNT7B expression through canonical SMAD4-dependent mechanisms.

The genes involved in the pathogenesis of pancreatic cancer can be divided into three categories: tumor-suppressor genes, oncogenes, and DNA mismatch-repair genes. Understanding these mutations is critical to better understanding familial pancreatic cancer and to developing gene-based screening tests and therapies. The most frequent genetic abnormalities in invasive pancreatic adenocarcinoma are mutational activation of Kras oncogene and inactivation of tumor suppressor genes, including CDKN2A, TP53, SMAD4, and BRCA2, widespread chromosomal losses, gene amplifications, and telomere shortening.

Chemotherapy is the main type of systemic therapy used for pancreatic cancer. However, targeted therapy and immunotherapy are occasionally used and are being studied as potential treatments in select individuals with specific molecular or genetic features. A person may receive one type of medication at a time or a combination of medications given at the same time. They can also be given as part of a treatment plan that includes surgery and/or radiation therapy. Patients with pancreatic cancer can choose from a variety of treatments. Clinical trials are being conducted to test various treatments, some of which are standard (currently used treatments). A new treatment might replace the standard one if clinical trials reveal that it is superior to the current one.

"Pancreatic Cancer - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Pancreatic Cancer.

Pancreatic Cancer Emerging Drugs Chapters

This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pancreatic Cancer Emerging Drugs

• Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

• Masitinib: AB Science

Masitinib (AB-1010) is an investigational drug for the treatment of metastatic pancreatic cancer. The drug candidate is administered orally. It is an ATP-binding site competitor. The drug candidate acts by inhibiting wild-type forms of c-KIT, Fyn, Lyn tyrosine kinase and platelet-derived growth factor receptor alpha and beta. Masitinib is a selective inhibitor of the tyrosine kinase inhibitor that targets KIT. Currently being evaluated in the Phase III studies.

• Glufosfamide: Eleison Pharmaceuticals LLC.

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs called as alkylators with a glucose molecule. Because of its glucose component and a tumor cell's increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylator is cleaved to release the active drug. Currently the drug is being evaluated in Phase III for the treatment of Pancreatic Cancer.

• Quemliclustat: Arcus Biosciences, Inc.

Quemliclustat is a potent and selective small molecule being developed by Arcus Biosciences. Inhibitor of CD73 that has been shown to block the production of adenosine. The reduction of adenosine restores immune function. The drug candidate is administered through intravenous and oral route. The drug candidate is currently in Phase III stage of clinical trial.

• CT041: CARsgen Therapeutics

CT041 is a potential first in class autologous chimeric antigen receptor CAR T-cell product candidate that targets the protein CLDN18.2. CT041 targets the treatment of CLDN18.2 positive solid tumors with a primary focus on pancreatic cancer. The drug candidate presently is in Phase II stage.

• DK210: DEKA Biosciences

DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka's platform of molecules, which combines the cytokines full strength IL-2 and a high affinity IL-10. While IL-2 is known to be toxic, when coupled with IL-10, toxicity is not only reduced but its potency is increased, thereby creating a more tolerable and effective treatment for patients. It is the first of several experimental therapeutics in Deka's platform of molecules which are being developed to treat both cancer and inflammatory diseases. These therapeutics, known as DiakinesTM, involve coupling two cytokines together onto a single chain variable fragment (scFv) targeting system to enhance their precision in targeting specific tissues. Furthermore, the scFv scaffold used in the DiakineTM platform also improves efficacy, safety and manufacturability of each treatment. The drug candidate presently is in Phase I stage for the treatment of pancreatic cancer.

• CT7001: Carrick Therapeutics

Samuraciclib is the most advanced CDK7 inhibitor in clinical development. Inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and promotes resistance to anti-hormone therapy. Samuraciclib has demonstrated a favorable safety profile and encouraging efficacy in early clinical studies. In addition to the above studies, samuraciclib has further potential in prostate, pancreatic, ovarian and colorectal cancers. Samuraciclib has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for use in combination with fulvestrant for the treatment of CDK4/6i resistant HR+, HER2- advanced breast cancer. Carrick is collaborating with Roche, Menarini Group and Arvinas/Pfizer to evaluate novel combinations of samuraciclib with Roche's oral SERD giredestrant, Menarini Group's oral SERD elacestrant, and Arvinas/Pfizer's proteolysis targeting chimera (PROTAC) Estrogen Receptor degrader vepdegestrant (ARV-471) in late-stage CDK4/6i resistant HR+, HER2- metastatic breast cancer. Currently the drug is in preclinical stage of its development for the treatment of pancreatic cancer.

Pancreatic Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pancreatic Cancer

There are approx. 170+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen

• Phases

Delve Insight's report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pancreatic Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.

Pancreatic Cancer Report Insights

• Pancreatic Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pancreatic Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pancreatic Cancer drugs?
• How many Pancreatic Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatic Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Fibrogen
• AB Science
• Eleison Pharmaceuticals LLC
• Janssen Pharmaceuticals
• CARsgen Therapeutics
• Arcus Biosciences, Inc.
• Chia Tai Tianqing Pharmaceutical Group
• Innovent Biologics
• Amgen
• Biomea Fusion
• Prestige Biopharma Limited
• Bristol-Myers Squibb
• GlaxoSmithKline
• Incyte Corporation
• Helix BioPharma
• Genentech, Inc.
• ENB Therapeutics
• Carrick Therapeutics
• Avenge Bio
• DEKA Biosciences
• Keymed Biosciences
• Pfizer
• Redx Pharma Plc
• AIM ImmunoTech Inc.

Key Products

• Pamrevlumab
• Masitinib
• Glufosfamide
• Niraparib
• CT041
• Quemliclustat
• TQB 2858
• NGM120
• ENB003
• CT7001
• AVB002
• DK210
• CMG901
• AB011
• Ponsegromab
• RXC004
• Rintatolimod